{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:46:33Z","timestamp":1778813193452,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P41-GM103311"],"award-info":[{"award-number":["P41-GM103311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.compbiomed.2020.104137","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T01:59:41Z","timestamp":1606096781000},"page":"104137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-5759","authenticated-orcid":false,"given":"Susmit","family":"Mhatre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivraj","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Patravale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2020.104137_bib1","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.compbiomed.2020.104137_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV - a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.compbiomed.2020.104137_bib3","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.compbiomed.2020.104137_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5114\/aoms.2020.94046","article-title":"State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2","volume":"16","author":"Azeez","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.compbiomed.2020.104137_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5114\/aoms.2020.94567","article-title":"State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2","volume":"16","author":"Borgio","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.compbiomed.2020.104137_bib6","article-title":"Classification of COVID-19 in chest X-ray images using DeTraC deep convolutional neural network","author":"Abbas","year":"2020","journal-title":"Appl. Intell."},{"key":"10.1016\/j.compbiomed.2020.104137_bib7","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/jn\/130.10.2409","article-title":"Effects of tea consumption on nutrition and health","volume":"130","author":"Yang","year":"2000","journal-title":"J. Nutr."},{"key":"10.1016\/j.compbiomed.2020.104137_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1749-8546-5-13","article-title":"Beneficial effects of green tea: a literature review","volume":"5","author":"Chacko","year":"2010","journal-title":"Chin. Med."},{"key":"10.1016\/j.compbiomed.2020.104137_bib9","first-page":"153286","article-title":"Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: a review","author":"Mhatre","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.compbiomed.2020.104137_bib10","first-page":"1","article-title":"Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors \u2013 an in silico docking and molecular dynamics simulation study","author":"Ghosh","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2020.104137_bib11","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.3390\/ijms21145171","article-title":"Protective effect of epigallocatechin-3-gallate (EGCG) in diseases with uncontrolled immune activation: could such a scenario Be helpful to counteract COVID-19?","volume":"21","author":"Menegazzi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2020.104137_bib12","author":"Adem"},{"key":"10.1016\/j.compbiomed.2020.104137_bib13","first-page":"1","article-title":"Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors","author":"Bhardwaj","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2020.104137_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2005.06.010","article-title":"Antiviral effect of catechins in green tea on influenza virus","volume":"68","author":"Song","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.compbiomed.2020.104137_bib15","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1038\/sj.emboj.7601368","article-title":"A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus","volume":"25","author":"Imbert","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.compbiomed.2020.104137_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.yrtph.2018.03.019","article-title":"The safety of green tea and green tea extract consumption in adults \u2013 results of a systematic review","volume":"95","author":"Hu","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.compbiomed.2020.104137_bib17","author":"Frank"},{"key":"10.1016\/j.compbiomed.2020.104137_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2007-971549","article-title":"Inhibition of passive cutaneous anaphylaxis by compounds of Camellia sinensis","volume":"42","author":"Kar","year":"1981","journal-title":"Planta Med."},{"key":"10.1016\/j.compbiomed.2020.104137_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2020.104137_bib20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.str.2011.03.019","article-title":"A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions","volume":"19","author":"Shapovalov","year":"2011","journal-title":"Structure"},{"key":"10.1016\/j.compbiomed.2020.104137_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.compbiomed.2020.104137_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004586","article-title":"AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility","volume":"11","author":"Ravindranath","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.compbiomed.2020.104137_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2020.104137_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/bioinformatics\/btw638","article-title":"PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL","volume":"33","author":"Janson","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.compbiomed.2020.104137_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6026\/97320630009224","article-title":"In Silico mutagenesis and docking studies of active site residues suggest altered substrate specificity and possible physiological role of Cinnamoyl CoA Reductase 1 (Ll-CCRH1)","volume":"9","author":"Sonawane","year":"2013","journal-title":"Bioinformation"},{"key":"10.1016\/j.compbiomed.2020.104137_bib26","doi-asserted-by":"crossref","first-page":"W350","DOI":"10.1093\/nar\/gky300","article-title":"DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability","volume":"46","author":"Rodrigues","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2020.104137_bib27","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2020.104137_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.compbiomed.2020.104137_bib29","doi-asserted-by":"crossref","DOI":"10.1063\/5.0014475","article-title":"Scalable molecular dynamics on CPU and GPU architectures with NAMD","volume":"153","author":"Phillips","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2020.104137_bib30","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2020.104137_bib31","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2020.104137_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jmb.2009.05.015","article-title":"Understanding the functional roles of amino acid residues in enzyme catalysis","volume":"390","author":"Holliday","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.compbiomed.2020.104137_bib33","first-page":"1","article-title":"Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach","author":"Mahanta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2020.104137_bib34","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1021\/acs.jpclett.0c00994","article-title":"In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2\u2019s main protease","volume":"11","author":"Huynh","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.compbiomed.2020.104137_bib35","first-page":"1","article-title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes","author":"Elmezayen","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2020.104137_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.compbiomed.2020.104137_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1871528114666151022150122","article-title":"Compounds derived from epigallocatechin-3-gallate (EGCG) as a novel approach to the prevention of viral infections","volume":"14","author":"Hsu","year":"2015","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.compbiomed.2020.104137_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2174\/187152812803251033","article-title":"A proprietary topical preparation containing EGCG-stearate and glycerin with inhibitory effects on herpes simplex virus: case study","volume":"11","author":"Zhao","year":"2012","journal-title":"Inflamm. Allergy - Drug Targets"}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482520304686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482520304686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T19:30:10Z","timestamp":1757878210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482520304686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"alternative-id":["S0010482520304686"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2020.104137","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2020.104137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104137"}}